A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (PROSPERO)

Chronic Obstructive Pulmonary Disease (COPD)

Annualized rate of severe COPD exacerbation for Tozorakimab versus placebo in former smokers.

Annualised rate of severe COPD exacerbations in former or current smokers., Time to first severe COPD exacerbations in former smokers., Time to first severe COPD exacerbations in former or current smokers., Time to First Moderate to Severe COPD Exacerbation., Annualised Rate of Moderate-to-Severe COPD Exacerbations., Time to Death (All-cause mortality)., Pharmacokinetics, Immunogenicity, To assess the long-term safety and tolerability of tozorakimab, Annualised rate of COPD exacerbations requiring hospitalisation and/or ER/ED visits in former smokers., Annualised rate of COPD exacerbations requiring hospitalisation and/or ER/ED visits in former or current smokers.

No related papers found yet.

Belgium, Bulgaria, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Netherlands, Norway, Poland, Portugal, Romania, Spain, Sweden